D. Cushing

发表

Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (Pro11,D-Ala12)-angiotensin I.

K. W. Hoover, M. Mangiapane, D. Knight, 1994, Hypertension.

PM101: intravenous amiodarone formulation changes can improve medication safety

P. Souney, D. Cushing, W. D. Cooper, 2010, Expert opinion on drug safety.

Comparative Bioavailability of a Premixed, Ready‐to‐Use Formulation of Intravenous Amiodarone With Traditional Admixture in Healthy Subjects

P. Souney, D. Cushing, W. D. Cooper, 2012, Journal of clinical pharmacology.

Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans

S. Machatha, P. Kowey, P. Souney, 2012, Clinical and Experimental Pharmacology and Physiology.

Serotonin-induced contraction in canine coronary artery and saphenous vein: role of a 5-HT1D-like receptor.

M. Cohen, M. Baez, K. Schenck, 1994, Life sciences.

Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.

S. Oparil, E. Michelson, W. White, 1998, The American journal of cardiology.

Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.

E. Michelson, P. Deedwania, A. Lewin, 1999, Heart disease.

The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period

R. Lipicky, M. Gralinski, D. Cushing, 2010, Clinical and experimental pharmacology & physiology.

PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects.

P. Kowey, R. Lipicky, B. W. Massey, 2009, European journal of pharmacology.

Characterization of adenosine binding sites in bovine testicular tissue using 8-cyclopentyl-1,3-[3H]dipropylxanthine.

Syed Jamal Mustafa, M. McConnaughey, D. Cushing, 1988, European journal of pharmacology.

Adenosine receptor-mediated coronary artery relaxation and cyclic nucleotide production.

Syed Jamal Mustafa, G. Brown, D. Cushing, 1991, The American journal of physiology.

Inhibition of adenylate cyclase attenuates adenosine receptor-mediated relaxation in coronary artery.

Syed Jamal Mustafa, D. Cushing, M. Sabouni, 1991, The Journal of pharmacology and experimental therapeutics.

The Effects of Various Adenosine and Xanthine Analogues on Mammalian Sperm Motility

D. Cushing, 1986 .

Comparison of the serotonin receptors that mediate smooth muscle contraction in canine and porcine coronary artery.

M. Cohen, D. Cushing, 1992, The Journal of pharmacology and experimental therapeutics.

Comparison of the Cardiac Electrophysiology and General Toxicology of Two Formulations of Intravenous Amiodarone in Dogs

P. Kudenchuk, P. Kowey, R. Lipicky, 2009, Cardiovascular Toxicology.

A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.

E. Dees, M. Klichinsky, J. Bauml, 2021 .

Is the "atypical" beta-receptor in the rat stomach fundus the rat beta 3 receptor?

J. Granneman, M. Cohen, A. Palkowitz, 1995, Journal of Pharmacology and Experimental Therapeutics.

Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.

E. Michelson, M. Munger, A. Carr, 1999, Clinical therapeutics.

Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators.

E. Michelson, V. Dequattro, D. Ruff, 1999, The American journal of cardiology.

Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.

S. Oparil, E. Michelson, J. Levine, 1998, The American journal of cardiology.

Overview: 5-HT2 Receptor Antagonists for the Treatment of Cardiovascular Disease

Marlene L. Cohen, D. Cushing, J. Misner, 1993 .

Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist.

Robert B. Harris, M. Sobel, Marlene L. Cohen, 2010, European journal of pharmacology.

Interaction of the beta adrenergic receptor antagonist bucindolol with serotonergic receptors.

G. Fink, S. Watts, P. Silver, 2000, Journal of cardiovascular pharmacology.

Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity.

M. Cohen, D. Cushing, 1993, Journal of Pharmacology and Experimental Therapeutics.

Serotonin-induced relaxation in canine coronary artery smooth muscle.

M. Cohen, D. Cushing, 1992, The Journal of pharmacology and experimental therapeutics.

LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery.

J. Zgombick, D. Nelson, M. Cohen, 1996, The Journal of pharmacology and experimental therapeutics.

Fluoride produces endothelium-dependent relaxation and endothelium-independent contraction in coronary artery.

Syed Jamal Mustafa, G. Brown, D. Cushing, 1990, The Journal of pharmacology and experimental therapeutics.

G Proteins Subserve Relaxations Mediated by Adenosine Receptors in Human Coronary Artery

Syed Jamal Mustafa, T. Hussain, D. Cushing, 1990, Journal of cardiovascular pharmacology.

Bioequivalence of 2 Intravenous Amiodarone Formulations in Healthy Participants

P. Kowey, R. Lipicky, D. Cushing, 2009, Journal of clinical pharmacology.

PM101: intravenous amiodarone formulation changes can improve medication safety

P. Souney, D. Cushing, W. D. Cooper, 2010, Expert opinion on drug safety.

Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans.

P. Kowey, R. Lipicky, D. Cushing, 2009, The American journal of cardiology.